FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:599-603 August 27, 1998 Number 9 Next

PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

During childhood and young adulthood, the skeleton accrues virtually all the bone mineral it will ever have.¹ Since the aging process is associated with bone loss, the more bone mass one gains in the formative years, the less likely it is that increased bone resorption and decreased bone formation will result in osteoporosis. Hence, the failure to achieve optimal peak bone mass is a pathogenetic mechanism in osteoporosis. The sex steroids are critically important in helping to establish peak bone mass for both sexes. Girls with estrogen deficiency do not achieve optimal peak bone mass.^2,3,4 Similarly, achievement of peak bone mass is compromised in boys with hypogonadism and those in whom puberty is delayed.^5,6

Two rare genetic disorders associated with estrogen resistance or estrogen deficiency suggest that androgens are not solely responsible for the establishment of peak bone mass in males. Smith et al.⁷ described a man with estrogen resistance because of a point mutation in the estrogen-receptor gene. Morishima et al.⁸ and Carani et al.⁹ each described a man with a point mutation in exon 9 of the aromatase gene and an associated inability to convert androgen to estrogen (the man described by Morishima et al. is the patient discussed here). In these two genetic disorders associated with estrogen resistance or estrogen deficiency, osteoporosis was present.

To demonstrate clearly the importance of estrogens in establishing peak bone mass in growing males, it is important to show that replacement of estrogen, in the setting of lifelong estrogen deficiency, leads to restoration of bone mass. We now report the results of such a study, in which a young man with severe aromatase deficiency was treated with conjugated estrogen for three years.

Case Report

The patient was 24 years old. His 27-year-old sister, the propositus, was evaluated at birth because of ambiguous genitalia. Both the patient and his sister have been reported previously⁸ to have a homozygous point mutation in exon 9 of the aromatase gene, leading to a single-base-pair change at position 1123 and no enzyme activity. The parents were of Italian descent and were consanguineous. They were phenotypically normal, and each had a single copy of the mutant gene. The mother was 165 cm in height, and the father was 190 cm in height. The patient was 204 cm in height, with a eunuchoid appearance. He was heterosexual and sexually active. Macroorchidism was present, with an estimated total testicular volume of 34 ml. Bone age was 14.5 years; only the proximal femoral epiphyses were fused. The ratio of the upper segment to the lower segment was 0.84. Serum androgen concentrations were all markedly elevated, but serum estrone and estradiol concentrations were undetectable. Serum concentrations of follicle-stimulating hormone and luteinizing hormone were elevated (Table 1). Semen analysis was not done.

View this table: [in this window] [in a new window]   Table 1. Hormonal, Bone-Turnover, and Metabolic Indexes before and after Three Years of Estrogen Therapy.

 
Bone mass was reduced at all sites. The reductions in standard deviations from the mean for age- and sex-matched normal subjects (z scores) were 1.68 at the lumbar spine, 0.53 at the femoral neck, and 4.65 at the left radius (one third the distance from the wrist to the elbow). Determinations of bone mass by dual-energy x-ray absorptiometry, which assesses two-dimensional area density, are subject to an artifact of size relative to volumetric density^10,11,12 according to the following equations: the apparent bone mineral density of the lumbar spine = bone mineral content ÷ A_p^3/2; the apparent bone mineral density of the femoral neck and radius = bone mineral content ÷ A_p², where A_p denotes projected area. Thus, the patient's apparent bone mineral density was even more impressively reduced than his area density. The calculated apparent bone mineral density was lower than the measured area density by 19 percent in the lumbar spine (–1.99 SD), by 75 percent in the femoral neck (–2.12 SD), and by 60 percent in the radius (–7.75 SD). This report presents standard two-dimensional area units because this method of presentation of bone mineral density by dual-energy x-ray absorptiometry is more familiar.

Methods

Biochemical Determinations

Serum 5-dihydrotestosterone, androstenedione, and testosterone were measured by Mayo Medical Laboratories (Rochester, Minn.). Serum estrone, estradiol, follicle-stimulating hormone, luteinizing hormone, osteocalcin, and bone-specific alkaline phosphatase activity were measured by SmithKline Beecham Laboratories (Syosset, N.Y.). Urinary deoxypyridinoline, pyridinoline, and creatinine were measured with the use of Corning Nichols Institute (San Juan Capistrano, Calif.). Urinary calcium was measured with the use of atomic absorption spectroscopy.

Bone Densitometry

Sequential bone densitometry was performed over the three-year period on the same machine, a QDR 1000W densitometer (Hologic, Waltham, Mass.). In our hands, the precision was 0.68 percent at the lumbar spine, 1.36 percent at the femoral neck, and 0.70 percent at the distal radius.

Results

With his informed consent, the patient was treated with conjugated estrogens (Premarin). The initial daily dose of 0.3 mg was gradually increased during the first 12 months to 0.75 mg, which is the dose he is still taking. Shortly after the initiation of estrogen treatment, linear growth, which had been continuous, ceased. All epiphyses of the hand and wrist were completely fused within six months (Figure 1). Serum estrone and estradiol concentrations rose into the normal range for men within the first three months and remained at or slightly above normal thereafter (Table 1). The increase in serum estrogen concentrations was accompanied by a gradual reduction in serum testosterone and 5-dihydrotestosterone concentrations. The patient's serum luteinizing hormone and follicle-stimulating hormone concentrations decreased to levels that were slightly higher than normal (Table 1). The estimated testicular volume decreased from 34 to 28 ml.

View larger version (70K): [in this window] [in a new window]   Figure 1. Growth Curve and Bone Age before and after Three Years of Estrogen Therapy. After the institution of estrogen therapy (bar), linear growth ceased immediately, and height remained at 204 cm. The epiphyses closed within six months (insets). At a chronologic age of 24.5 years, the patient's bone age was 14.5 years (A). His bone age matured with closure of epiphyses after therapy (B). The numbered curves represent the mean and standard deviations in normal young men.

 
Markers of bone turnover gradually approached normal values (Table 1). Within 18 months, urinary concentrations of calcium, pyridinoline, and deoxypyridinoline were normal. In contrast, serum alkaline phosphatase activity did not begin to fall until after 18 months of therapy. Even after 36 months of therapy, serum alkaline phosphatase activity was 136 IU per liter, which was still above the normal range of 39 to 117 IU per liter.

Bone mass increased dramatically at all sites. At one year, bone mass in the lumbar spine, femoral neck, and distal radius had increased by 7.7 percent, 9.8 percent, and 6.8 percent, respectively. Increases in bone mass continued, and by three years, the increase was 20.7 percent in the lumbar spine, 15.7 percent in the femoral neck, and 12.9 percent in the distal radius (Figure 2). These percentage increases correspond to the following increases in grams per square centimeter: lumbar spine, from 0.931 to 1.123; femoral neck, 0.920 to 1.060; and distal radius, 0.570 to 0.643. When these results were expressed as improvements in T scores (standard deviations from the mean in normal young men), the bone mass increased from –1.96 to +0.08 in the lumbar spine, from –0.36 to +0.96 in the femoral neck, and from –4.65 to –3.28 in the distal radius.

View larger version (9K): [in this window] [in a new window]   Figure 2. Changes in Bone Density during Estrogen Therapy. The percentage increase from base-line values is shown for each site. After the base-line determination, specific measurements were made at 12, 30, and 36 months.

 
There were no changes in serum concentrations of calcium, phosphorus, parathyroid hormone, 25-hydroxyvitamin D, or 1,25-dihydroxyvitamin D, all of which were normal. The base-line serum insulin concentration was elevated (52 µU per milliliter) when the plasma fasting glucose concentration was normal, indicating a state of insulin resistance (Table 1). The serum insulin concentrations gradually became normal during therapy without any changes in the fasting plasma glucose or glycosylated hemoglobin values. Similarly, the initially elevated serum concentrations of triglycerides and low-density lipoprotein cholesterol became normal. The changes in serum concentrations of insulin, low-density lipoprotein cholesterol, and triglycerides provide further evidence of the importance of estrogen in carbohydrate and lipid metabolism.^{13,14,15,16,17} Correction of the lipid abnormalities could also have been due, in part, to normalization of the high serum androgen concentrations.^18,19

The patient reported no side effects from estrogen therapy. He did not gain weight, develop gynecomastia, or have mood disturbances. He had no change in libido or sexual orientation.

Discussion

The case we describe illustrates the essential role of estrogens in skeletal development in males. Reports of osteoporosis in humans and animals with gene defects in the estrogen receptor^7,20,21 and in patients with aromatase deficiency have called attention to the importance of estrogens in skeletal growth. But it remained to be shown that correction of the specific estrogen deficit with estrogen could restore bone mass. The hypothesis that estrogen replacement would be beneficial could not be tested in the patient described by Smith et al.⁷ because of a defective estrogen receptor.

In a male patient with aromatase deficiency studied by Carani et al.,⁹ estrogen was administered for only six months, and skeletal measurement was restricted to the lumbar spine. In addition, that patient's aromatase deficiency was complicated by a hypothalamic–pituitary–gonadal disorder. In the only study of an affected female for whom bone densitometric data are available, Mullis et al.²² reported changes in a three-year-old girl, but over an even shorter period of time. No data on bone mineral density in other girls with aromatase deficiency have been reported.^{23,24,25,26,27,28} In the patient we describe, conjugated estrogens were given continuously for three years, with beneficial results at the lumbar spine, hip region, and distal radius.

Previous notions that the male skeleton accrues more mass than the female skeleton because of its greater exposure to androgens must now be reconsidered. It appears that both androgens and estrogens are important and that, together, they are the critical determinants of peak mass in the male skeleton. This conclusion is supported by the finding of Vanderschueren et al.²⁹ that male rats require both androgens and estrogens for optimal skeletal growth. Similarly, for optimal peak bone mass in women, androgens and estrogens are important.^30,31 The results of the present study document that in males both androgens and estrogens are required for optimal peak bone mass.

The gain in bone mass was due to a true net anabolic effect, because after estrogen therapy was instituted, the patient immediately stopped growing and, as in the patient described by Carani et al.,⁹ all epiphyses fused. Furthermore, there were no substantial increases in bone size after the epiphyses closed. Thus, gains in bone mass accurately reflect accrual of bone mineral rather than a mixture of growth effects on the skeleton. This is especially important to note because the results of dual-energy x-ray absorptiometry are subject to changes due to increments in two-dimensional skeletal size that do not necessarily reflect a true change in volumetric density.^10,11,12 The mechanisms of bone accrual are likely to be due both to the antiresorptive effects of estrogens³² and to direct anabolic effects. A direct anabolic effect is inferred because it is difficult to account for the remarkable increase in bone mass by an exclusive antiresorptive effect, given the moderate elevations in bone turnover before therapy and the interval over which the improvement occurred.³³

Improvements in bone mass in this patient are particularly remarkable, considering the fact that estrogen therapy also reduced androgen concentrations to normal levels. The explanation for the elevated androgen concentrations is twofold. First, because of the complete absence of aromatase activity, no testosterone was metabolized by conversion to estrogen. Second, the elevated serum concentrations of luteinizing hormone stimulated the Leydig cells to overproduce androgen. The elevation in serum concentrations of luteinizing hormone and follicle-stimulating hormone suggests that estrogen, in addition to testosterone and inhibin, has an important role in regulating the secretion of both gonadotropins.^34,35,36 When estrogen was deficient, the gonadotropin concentrations were elevated; with estrogen replacement, they became normal. The fact that bone mass increased when the androgen concentrations were declining strengthens the case for a specific anabolic effect of estrogen on the skeleton in males.

We conclude that estrogen is essential for the establishment of peak bone mass in growing boys, as well as for the maintenance of bone mass in adult men. Several recent studies have provided evidence of the latter point. Slemenda et al.³⁷ and others^38,39,40,41 have shown that the slow, age-related decline in bone mass in men is more directly related to declining estrogen concentrations than to declining androgen concentrations. It is also possible that the therapeutic effects of androgens in men with osteoporosis are due in part to their conversion to estrogens.⁴² With regard to the developing skeleton in males, the results of our study demonstrate the importance of estrogen sufficiency in the establishment of peak bone mass.

Supported in part by the Partnership for Women's Health (Columbia University and Procter & Gamble).

We are indebted to Dr. Elizabeth Shane for helpful discussions and to Dr. Evan Simpson for earlier work on the molecular features of this patient's disorder.

Source Information

From the Departments of Medicine (J.P.B.), Pharmacology (J.P.B.), and Pediatrics (A.M., J.B.), College of Physicians and Surgeons, Columbia University, New York; and the Department of Pediatrics, University of California, San Francisco (M.M.G.). Presented in abstract form at the 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, September 10–14, 1997 (J Bone Miner Res 1997;12:Suppl:S678).

Address reprint requests to Dr. Bilezikian at the Department of Medicine, College of Physicians and Surgeons, 630 W. 168th St., New York, NY 10032.

References

1. Bonjour J-P, Rizzoli R. Bone acquisition in adolescence. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego, Calif.: Academic Press, 1996:465-76. 
2. Bachrach LK, Guido D, Katzman D, Litt IF, Marcus R. Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics 1990;86:440-447. [Free Full Text]
3. Warren MP, Brooks-Gunn J, Hamilton LH, Warren LF, Hamilton WG. Scoliosis and fractures in young ballet dancers: relation to delayed menarche and secondary amenorrhea. N Engl J Med 1986;314:1348-1353. [Erratum, N Engl J Med 1986;315:905.] [Abstract]
4. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF Jr. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987;106:354-361.
5. Finkelstein JS, Neer RM, Biller BMK, Crawford JD, Klibanski A. Osteopenia in men with a history of delayed puberty. N Engl J Med 1992;326:600-604. [Abstract]
6. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995;16:87-116. [Free Full Text]
7. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056-1061. [Erratum, N Engl J Med 1995;332:131.] [Free Full Text]
8. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-3698. [Abstract]
9. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91-95. [Free Full Text]
10. Katzman DK, Bachrach LK, Carter DR, Marcus R. Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab 1991;73:1332-1339. [Free Full Text]
11. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992;7:137-145. [Medline]
12. Genant HK, Engelke K, Fuerst R, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996;11:707-730. [Medline]
13. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB. Effects of low doses of transdermal 17beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992;74:1396-1400. [Abstract]
14. Godsland IF, Gangar KF, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-853. [CrossRef][Medline]
15. Sharp SC, Diamond MP. Sex steroids and diabetes. Diabetes Rev 1995;1:318-42.
16. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199-208. [Erratum, JAMA 1995;274:1676.] [Free Full Text]
17. Bagatell CJ, Knopp RH, Rivier JE, Bremner WJ. Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men. J Clin Endocrinol Metab 1994;78:855-861. [Abstract]
18. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier RE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 1994;79:561-567. [Abstract]
19. Asscheman H, Gooren LJ, Megens JA, Nauta J, Kloosterboer HJ, Eikelboom F. Serum testosterone level is the major determinant of the male-female differences in serum levels of high-density lipoprotein (HDL) cholesterol and HDL2 cholesterol. Metabolism 1994;43:935-939. [CrossRef][Medline]
20. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 1993;90:11162-11166. [Free Full Text]
21. Korach KS. Insights from the study of animals lacking functional estrogen receptor. Science 1994;266:1524-1527. [Free Full Text]
22. Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P, Harada H. Aromatase deficiency in a female who is a compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metab 1997;82:1739-1745. [Free Full Text]
23. Shozu M, Akasofu K, Harada T, Kubota Y. A new cause of female pseudohermaphroditism: placental aromatase deficiency. J Clin Endocrinol Metab 1991;72:560-566. [Free Full Text]
24. Ito Y, Fisher CR, Conte FA, Grumbach MM, Simpson ER. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci U S A 1993;90:11673-11677. [Free Full Text]
25. Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab 1994;78:1287-1292. [Abstract]
26. Harada N, Ogawa H, Shozu M, et al. Biochemical and molecular genetic analyses on placental aromatase (P-450AROM) deficiency. J Biol Chem 1992;267:4781-4785. [Free Full Text]
27. Harada N, Ogawa H, Shozu M, Yamada K. Genetic studies to characterize the origin of the mutation in placental aromatase deficiency. Am J Hum Genet 1992;51:666-672. [Medline]
28. Portrat-Doyen S, Forest MG, Nicolino M, Morel Y, Chatelain PC. Female pseudohermaphroditism (FPH) resulting from aromatase (P450_AROM) deficiency associated with a novel mutation (R457X) in the CYP19 gene. Horm Res 1996;46:Suppl 2:4-4.abstract
29. Vanderschueren D, van Herck E, Nijs J, Ederveen AGH, De Coster R, Bouillon R. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Endocrinology 1997;138:2301-2307. [Free Full Text]
30. Vanderschueren D, Bouillon R. Androgens and bone. Calcif Tissue Int 1995;56:341-346. [CrossRef][Medline]
31. Davis SR, Burger HG. Androgens and the postmenopausal woman. J Clin Endocrinol Metab 1996;81:2759-2763. [Free Full Text]
32. Lindsay R, Cosman F. The pharmacology of estrogens in osteoporosis. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. San Diego, Calif.: Academic Press, 1996:1063-6.
33. Heaney RP. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 1994;9:1515-1523. [Medline]
34. Finkelstein JS, O'Dea LS, Whitcomb RW, Crowley WJ Jr. Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 1991;73:621-628. [Free Full Text]
35. Bagatell CJ, Dahl KD, Bremner WJ. The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol. J Androl 1994;15:15-21. [Free Full Text]
36. Kletter GB, Padmanabhan V, Beitins IZ, Marshall JC, Kelch RP, Foster CM. Acute effects of estradiol infusion and naloxone on luteinizing hormone secretion in pubertal boys. J Clin Endocrinol Metab 1997;82:4010-4014. [Free Full Text]
37. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC. Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997;100:1755-1759. [Medline]
38. Greendale GA, Edelstein ES, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997;12:1833-1843. [CrossRef][Medline]
39. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-2274. [Free Full Text]
40. Bernecker PM, Willvonsder R, Resch H. Decreased estrogen levels in male patients with primary osteoporosis. J Bone Miner Res 1995;10:Suppl:S445-S445.abstract 
41. Center JR, Nguyen TV, White CP, Eisman JA. Male osteoporosis predictors: sex hormones and calcitropic hormones. J Bone Miner Res 1997;12:Suppl 1:S368-S368.abstract 
42. Anderson FH, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res 1997;12:472-478. [CrossRef][Medline]

PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

This article has been cited by other articles:

• Gentile, M. A, Nantermet, P. V, Vogel, R. L, Phillips, R., Holder, D., Hodor, P., Cheng, C., Dai, H., Freedman, L. P, Ray, W. J (2010). Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of {beta}-catenin. J Mol Endocrinol 44: 55-73 [Abstract] [Full Text]  
• Lapauw, B., Taes, Y., Goemaere, S., Toye, K., Zmierczak, H.-G., Kaufman, J.-M. (2009). Anthropometric and Skeletal Phenotype in Men with Idiopathic Osteoporosis and Their Sons Is Consistent with Deficient Estrogen Action during Maturation. J. Clin. Endocrinol. Metab. 94: 4300-4308 [Abstract] [Full Text]  
• Ohlsson, C., Vandenput, L. (2009). The role of estrogens for male bone health. Eur J Endocrinol 160: 883-889 [Abstract] [Full Text]  
• Windahl, S. H., Andersson, N., Chagin, A. S., Martensson, U. E. A., Carlsten, H., Olde, B., Swanson, C., Moverare-Skrtic, S., Savendahl, L., Lagerquist, M. K., Leeb-Lundberg, L. M. F., Ohlsson, C. (2009). The role of the G protein-coupled receptor GPR30 in the effects of estrogen in ovariectomized mice. Am. J. Physiol. Endocrinol. Metab. 296: E490-E496 [Abstract] [Full Text]  
• Jankowski, C. M., Gozansky, W. S., Kittelson, J. M., Van Pelt, R. E., Schwartz, R. S., Kohrt, W. M. (2008). Increases in Bone Mineral Density in Response to Oral Dehydroepiandrosterone Replacement in Older Adults Appear to Be Mediated by Serum Estrogens. J. Clin. Endocrinol. Metab. 93: 4767-4773 [Abstract] [Full Text]  
• Smith, E. P., Specker, B., Bachrach, B. E., Kimbro, K. S., Li, X. J., Young, M. F., Fedarko, N. S., Abuzzahab, M. J., Frank, G. R., Cohen, R. M., Lubahn, D. B., Korach, K. S. (2008). Impact on Bone of an Estrogen Receptor-{alpha} Gene Loss of Function Mutation. J. Clin. Endocrinol. Metab. 93: 3088-3096 [Abstract] [Full Text]  
• Jones, T. S., Kaste, S. C., Liu, W., Cheng, C., Yang, W., Tantisira, K. G., Pui, C.-H., Relling, M. V. (2008). CRHR1 Polymorphisms Predict Bone Density in Survivors of Acute Lymphoblastic Leukemia. JCO 26: 3031-3037 [Abstract] [Full Text]  
• Khosla, S., Amin, S., Orwoll, E. (2008). Osteoporosis in Men. Endocr. Rev. 29: 441-464 [Abstract] [Full Text]  
• Loves, S., Ruinemans-Koerts, J., de Boer, H. (2008). Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 158: 741-747 [Abstract] [Full Text]  
• Yialamas, M. A., Dwyer, A. A., Hanley, E., Lee, H., Pitteloud, N., Hayes, F. J. (2007). Acute Sex Steroid Withdrawal Reduces Insulin Sensitivity in Healthy Men with Idiopathic Hypogonadotropic Hypogonadism. J. Clin. Endocrinol. Metab. 92: 4254-4259 [Abstract] [Full Text]  
• Syed, F. A., Fraser, D. G., Spelsberg, T. C., Rosen, C. J., Krust, A., Chambon, P., Jameson, J. L., Khosla, S. (2007). Effects of Loss of Classical Estrogen Response Element Signaling on Bone in Male Mice. Endocrinology 148: 1902-1910 [Abstract] [Full Text]  
• Lin, L., Ercan, O., Raza, J., Burren, C. P., Creighton, S. M., Auchus, R. J., Dattani, M. T., Achermann, J. C. (2007). Variable Phenotypes Associated with Aromatase (CYP19) Insufficiency in Humans. J. Clin. Endocrinol. Metab. 92: 982-990 [Abstract] [Full Text]  
• Rochira, V., Zirilli, L., Genazzani, A. D, Balestrieri, A., Aranda, C., Fabre, B., Antunez, P., Diazzi, C., Carani, C., Maffei, L. (2006). Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback.. Eur J Endocrinol 155: 513-522 [Abstract] [Full Text]  
• Ralston, S. H., de Crombrugghe, B. (2006). Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev. 20: 2492-2506 [Abstract] [Full Text]  
• Sobel, V., Schwartz, B., Zhu, Y.-S., Cordero, J. J., Imperato-McGinley, J. (2006). Bone Mineral Density in the Complete Androgen Insensitivity and 5{alpha}-Reductase-2 Deficiency Syndromes. J. Clin. Endocrinol. Metab. 91: 3017-3023 [Abstract] [Full Text]  
• Bilezikian, J. P. (2006). What's Good for the Goose's Skeleton is Good for the Gander's Skeleton.. J. Clin. Endocrinol. Metab. 91: 1223-1225 [Full Text]  
• Vanderschueren, D., Venken, K., Ophoff, J., Bouillon, R., Boonen, S. (2006). Sex Steroids and the Periosteum--Reconsidering the Roles of Androgens and Estrogens in Periosteal Expansion. J. Clin. Endocrinol. Metab. 91: 378-382 [Abstract] [Full Text]  
• Wang, Q., Alen, M., Nicholson, P. H. F., Halleen, J. M., Alatalo, S. L., Ohlsson, C., Suominen, H., Cheng, S. (2006). Differential Effects of Sex Hormones on Peri- and Endocortical Bone Surfaces in Pubertal Girls. J. Clin. Endocrinol. Metab. 91: 277-282 [Abstract] [Full Text]  
• Hero, M., Norjavaara, E., Dunkel, L. (2005). Inhibition of Estrogen Biosynthesis with a Potent Aromatase Inhibitor Increases Predicted Adult Height in Boys with Idiopathic Short Stature: A Randomized Controlled Trial. J. Clin. Endocrinol. Metab. 90: 6396-6402 [Abstract] [Full Text]  
• Greenspan, S. L., Coates, P., Sereika, S. M., Nelson, J. B., Trump, D. L., Resnick, N. M. (2005). Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer. J. Clin. Endocrinol. Metab. 90: 6410-6417 [Abstract] [Full Text]  
• Mueller, A., Dittrich, R., Binder, H., Kuehnel, W., Maltaris, T., Hoffmann, I., Beckmann, M. W (2005). High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. Eur J Endocrinol 153: 107-113 [Abstract] [Full Text]  
• Simpson, E. R., Misso, M., Hewitt, K. N., Hill, R. A., Boon, W. C., Jones, M. E., Kovacic, A., Zhou, J., Clyne, C. D. (2005). Estrogen--the Good, the Bad, and the Unexpected. Endocr. Rev. 26: 322-330 [Full Text]  
• Phillips, G. B. (2005). Is Atherosclerotic Cardiovascular Disease an Endocrinological Disorder? The Estrogen-Androgen Paradox. J. Clin. Endocrinol. Metab. 90: 2708-2711 [Abstract] [Full Text]  
• Watanabe, M., Ohno, S., Nakajin, S. (2005). Forskolin and dexamethasone synergistically induce aromatase (CYP19) expression in the human osteoblastic cell line SV-HFO. Eur J Endocrinol 152: 619-624 [Abstract] [Full Text]  
• Veldhuis, J. D., Bae, A., Swerdloff, R. S., Iranmanesh, A., Wang, C. (2005). Experimentally Induced Androgen Depletion Accentuates Ethnicity-Related Contrasts in Luteinizing Hormone Secretion in Asian and Caucasian Men. J. Clin. Endocrinol. Metab. 90: 1632-1638 [Abstract] [Full Text]  
• Veldhuis, J. D., Roemmich, J. N., Richmond, E. J., Rogol, A. D., Lovejoy, J. C., Sheffield-Moore, M., Mauras, N., Bowers, C. Y. (2005). Endocrine Control of Body Composition in Infancy, Childhood, and Puberty. Endocr. Rev. 26: 114-146 [Abstract] [Full Text]  
• Gennari, L., Nuti, R., Bilezikian, J. P. (2004). Aromatase Activity and Bone Homeostasis in Men. J. Clin. Endocrinol. Metab. 89: 5898-5907 [Abstract] [Full Text]  
• Bouillon, R., Bex, M., Vanderschueren, D., Boonen, S. (2004). Estrogens Are Essential for Male Pubertal Periosteal Bone Expansion. J. Clin. Endocrinol. Metab. 89: 6025-6029 [Abstract] [Full Text]  
• Arabi, A., Tamim, H., Nabulsi, M., Maalouf, J., Khalife, H., Choucair, M., Vieth, R., El-Hajj Fuleihan, G. (2004). Sex differences in the effect of body-composition variables on bone mass in healthy children and adolescents. Am. J. Clin. Nutr. 80: 1428-1435 [Abstract] [Full Text]  
• Valimaki, V.-V., Alfthan, H., Ivaska, K. K., Loyttyniemi, E., Pettersson, K., Stenman, U.-H., Valimaki, M. J. (2004). Serum Estradiol, Testosterone, and Sex Hormone-Binding Globulin as Regulators of Peak Bone Mass and Bone Turnover Rate in Young Finnish Men. J. Clin. Endocrinol. Metab. 89: 3785-3789 [Abstract] [Full Text]  
• Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., Ohlsson, C. (2004). Androgens and Bone. Endocr. Rev. 25: 389-425 [Abstract] [Full Text]  
• Gennari, L., Masi, L., Merlotti, D., Picariello, L., Falchetti, A., Tanini, A., Mavilia, C., Del Monte, F., Gonnelli, S., Lucani, B., Gennari, C., Brandi, M. L. (2004). A Polymorphic CYP19 TTTA Repeat Influences Aromatase Activity and Estrogen Levels in Elderly Men: Effects on Bone Metabolism. J. Clin. Endocrinol. Metab. 89: 2803-2810 [Abstract] [Full Text]  
• Wang, Q., Nicholson, P. H. F., Suuriniemi, M., Lyytikainen, A., Helkala, E., Alen, M., Suominen, H., Cheng, S. (2004). Relationship of Sex Hormones to Bone Geometric Properties and Mineral Density in Early Pubertal Girls. J. Clin. Endocrinol. Metab. 89: 1698-1703 [Abstract] [Full Text]  
• Khosla, S., Riggs, B. L., Atkinson, E. J., Oberg, A. L., Mavilia, C., Del Monte, F., Melton, L. J. III, Brandi, M. L. (2004). Relationship of Estrogen Receptor Genotypes to Bone Mineral Density and to Rates of Bone Loss in Men. J. Clin. Endocrinol. Metab. 89: 1808-1816 [Abstract] [Full Text]  
• Hewitt, K. N., Pratis, K., Jones, M. E. E., Simpson, E. R. (2004). Estrogen Replacement Reverses the Hepatic Steatosis Phenotype in the Male Aromatase Knockout Mouse. Endocrinology 145: 1842-1848 [Abstract] [Full Text]  
• Carel, J.-C., Lahlou, N., Roger, M., Chaussain, J. L. (2004). Precocious puberty and statural growth. Hum Reprod Update 10: 135-147 [Abstract] [Full Text]  
• Maffei, L., Murata, Y., Rochira, V., Tubert, G., Aranda, C., Vazquez, M., Clyne, C. D., Davis, S., Simpson, E. R., Carani, C. (2004). Dysmetabolic Syndrome in a Man with a Novel Mutation of the Aromatase Gene: Effects of Testosterone, Alendronate, and Estradiol Treatment. J. Clin. Endocrinol. Metab. 89: 61-70 [Abstract] [Full Text]  
• van der Eerden, B. C. J., Karperien, M., Wit, J. M. (2003). Systemic and Local Regulation of the Growth Plate. Endocr. Rev. 24: 782-801 [Abstract] [Full Text]  
• Drake, W. M., Kendler, D. L., Rosen, C. J., Orwoll, E. S. (2003). An Investigation of the Predictors of Bone Mineral Density and Response to Therapy with Alendronate in Osteoporotic Men. J. Clin. Endocrinol. Metab. 88: 5759-5765 [Abstract] [Full Text]  
• Lew, R., Komesaroff, P., Williams, M., Dawood, T., Sudhir, K. (2003). Endogenous Estrogens Influence Endothelial Function in Young Men. Circ. Res. 93: 1127-1133 [Abstract] [Full Text]  
• Seeman, E. (2003). Invited Review: Pathogenesis of osteoporosis. J. Appl. Physiol. 95: 2142-2151 [Abstract] [Full Text]  
• Muller, M., van der Schouw, Y. T., Thijssen, J. H. H., Grobbee, D. E. (2003). Endogenous Sex Hormones and Cardiovascular Disease in Men. J. Clin. Endocrinol. Metab. 88: 5076-5086 [Abstract] [Full Text]  
• Belgorosky, A., Pepe, C., Marino, R., Guercio, G., Saraco, N., Vaiani, E., Rivarola, M. A. (2003). Hypothalamic-Pituitary-Ovarian Axis during Infancy, Early and Late Prepuberty in an Aromatase-Deficient Girl Who Is a Compound Heterocygote for Two New Point Mutations of the CYP19 Gene. J. Clin. Endocrinol. Metab. 88: 5127-5131 [Abstract] [Full Text]  
• Gennari, L., Merlotti, D., Martini, G., Gonnelli, S., Franci, B., Campagna, S., Lucani, B., Dal Canto, N., Valenti, R., Gennari, C., Nuti, R. (2003). Longitudinal Association between Sex Hormone Levels, Bone Loss, and Bone Turnover in Elderly Men. J. Clin. Endocrinol. Metab. 88: 5327-5333 [Abstract] [Full Text]  
• Thompson, C. A., Shanafelt, T. D., Loprinzi, C. L. (2003). Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation. The Oncologist 8: 474-487 [Abstract] [Full Text]  
• Hewitt, K. N., Boon, W. C., Murata, Y., Jones, M. E. E., Simpson, E. R. (2003). The Aromatase Knockout Mouse Presents with a Sexually Dimorphic Disruption to Cholesterol Homeostasis. Endocrinology 144: 3895-3903 [Abstract] [Full Text]  
• Wickman, S., Kajantie, E., Dunkel, L. (2003). Effects of Suppression of Estrogen Action by the P450 Aromatase Inhibitor Letrozole on Bone Mineral Density and Bone Turnover in Pubertal Boys. J. Clin. Endocrinol. Metab. 88: 3785-3793 [Abstract] [Full Text]  
• Van Pottelbergh, I., Goemaere, S., Kaufman, J. M. (2003). Bioavailable Estradiol and an Aromatase Gene Polymorphism Are Determinants of Bone Mineral Density Changes in Men over 70 Years of Age. J. Clin. Endocrinol. Metab. 88: 3075-3081 [Abstract] [Full Text]  
• Benito, M., Gomberg, B., Wehrli, F. W., Weening, R. H., Zemel, B., Wright, A. C., Song, H. K., Cucchiara, A., Snyder, P. J. (2003). Deterioration of Trabecular Architecture in Hypogonadal Men. J. Clin. Endocrinol. Metab. 88: 1497-1502 [Abstract] [Full Text]  
• Misso, M. L., Murata, Y., Boon, W. C., Jones, M. E. E., Britt, K. L., Simpson, E. R. (2003). Cellular and Molecular Characterization of the Adipose Phenotype of the Aromatase-Deficient Mouse. Endocrinology 144: 1474-1480 [Abstract] [Full Text]  
• Ballock, R. T., O'Keefe, R. J. (2003). The Biology of the Growth Plate. JBJS 85: 715-726 [Full Text]  
• Leder, B. Z., LeBlanc, K. M., Schoenfeld, D. A., Eastell, R., Finkelstein, J. S. (2003). Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men. J. Clin. Endocrinol. Metab. 88: 204-210 [Abstract] [Full Text]  
• Herrmann, B. L., Saller, B., Janssen, O. E., Gocke, P., Bockisch, A., Sperling, H., Mann, K., Broecker, M. (2002). Impact of Estrogen Replacement Therapy in a Male with Congenital Aromatase Deficiency Caused by a Novel Mutation in the CYP19 Gene. J. Clin. Endocrinol. Metab. 87: 5476-5484 [Abstract] [Full Text]  
• Riggs, B. L., Khosla, S., Melton, L. J. III (2002). Sex Steroids and the Construction and Conservation of the Adult Skeleton. Endocr. Rev. 23: 279-302 [Abstract] [Full Text]  
• Kalantaridou, S. N., Chrousos, G. P. (2002). Monogenic Disorders of Puberty. J. Clin. Endocrinol. Metab. 87: 2481-2494 [Full Text]  
• Rochira, V., Balestrieri, A., Faustini-Fustini, M., Borgato, S., Beck-Peccoz, P., Carani, C. (2002). Pituitary Function in a Man with Congenital Aromatase Deficiency: Effect of Different Doses of Transdermal E2 on Basal and Stimulated Pituitary Hormones. J. Clin. Endocrinol. Metab. 87: 2857-2862 [Abstract] [Full Text]  
• Okazaki, R., Inoue, D., Shibata, M., Saika, M., Kido, S., Ooka, H., Tomiyama, H., Sakamoto, Y., Matsumoto, T. (2002). Estrogen Promotes Early Osteoblast Differentiation and Inhibits Adipocyte Differentiation in Mouse Bone Marrow Stromal Cell Lines that Express Estrogen Receptor (ER) {alpha} or {beta}. Endocrinology 143: 2349-2356 [Abstract] [Full Text]  
• Khosla, S., Melton, L. J. III, Riggs, B. L. (2002). Estrogen and the Male Skeleton. J. Clin. Endocrinol. Metab. 87: 1443-1450 [Abstract] [Full Text]  
• Pfeilschifter, J., Koditz, R., Pfohl, M., Schatz, H. (2002). Changes in Proinflammatory Cytokine Activity after Menopause. Endocr. Rev. 23: 90-119 [Abstract] [Full Text]  
• Mericq, V., Gajardo, H., Eggers, M., Avila, A., Cassorla, F. (2002). Effects of Treatment with GH Alone or in Combination with LHRH Analog on Bone Mineral Density in Pubertal GH-Deficient Patients. J. Clin. Endocrinol. Metab. 87: 84-89 [Abstract] [Full Text]  
• Manolagas, S.C., Kousteni, S., Jilka, R.L. (2002). Sex Steroids and Bone. Recent Prog Horm Res 57: 385-409 [Abstract] [Full Text]  
• Sopher, A. B., Thornton, J. C., Silfen, M. E., Manibo, A., Oberfield, S. E., Wang, J., Pierson, R. N. Jr., Levine, L. S., Horlick, M. (2001). Prepubertal Girls with Premature Adrenarche Have Greater Bone Mineral Content and Density Than Controls. J. Clin. Endocrinol. Metab. 86: 5269-5272 [Abstract] [Full Text]  
• Wickman, S., Dunkel, L. (2001). Inhibition of P450 Aromatase Enhances Gonadotropin Secretion in Early and Midpubertal Boys: Evidence for a Pituitary Site of Action of Endogenous E. J. Clin. Endocrinol. Metab. 86: 4887-4894 [Abstract] [Full Text]  
• Khosla, S., Melton, L. J. III, Atkinson, E. J., O'Fallon, W. M. (2001). Relationship of Serum Sex Steroid Levels to Longitudinal Changes in Bone Density in Young Versus Elderly Men. J. Clin. Endocrinol. Metab. 86: 3555-3561 [Abstract] [Full Text]  
• Szulc, P., Hofbauer, L. C., Heufelder, A. E., Roth, S., Delmas, P. D. (2001). Osteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status. J. Clin. Endocrinol. Metab. 86: 3162-3165 [Abstract] [Full Text]  
• Schnorr, J. A., Bray, M. J., Veldhuis, J. D. (2001). Aromatization Mediates Testosterone's Short-Term Feedback Restraint of 24-Hour Endogenously Driven and Acute Exogenous Gonadotropin-Releasing Hormone-Stimulated Luteinizing Hormone and Follicle-Stimulating Hormone Secretion in Young Men. J. Clin. Endocrinol. Metab. 86: 2600-2606 [Abstract] [Full Text]  
• Stoch, S. A., Parker, R. A., Chen, L., Bubley, G., Ko, Y.-J., Vincelette, A., Greenspan, S. L. (2001). Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists. J. Clin. Endocrinol. Metab. 86: 2787-2791 [Abstract] [Full Text]  
• Taxel, P., Kennedy, D. G., Fall, P. M., Willard, A. K., Clive, J. M., Raisz, L. G. (2001). The Effect of Aromatase Inhibition on Sex Steroids, Gonadotropins, and Markers of Bone Turnover in Older Men. J. Clin. Endocrinol. Metab. 86: 2869-2874 [Abstract] [Full Text]  
• Manolagas, S. C., Kousteni, S. (2001). Perspective: Nonreproductive Sites of Action of Reproductive Hormones. Endocrinology 142: 2200-2204 [Full Text]  
• Masi, L., Becherini, L., Gennari, L., Amedei, A., Colli, E., Falchetti, A., Farci, M., Silvestri, S., Gonnelli, S., Brandi, M. L. (2001). Polymorphism of the Aromatase Gene in Postmenopausal Italian Women: Distribution and Correlation with Bone Mass and Fracture Risk. J. Clin. Endocrinol. Metab. 86: 2263-2269 [Abstract] [Full Text]  
• Szulc, P., Munoz, F., Claustrat, B., Garnero, P., Marchand, F., Duboeuf, F., Delmas, P. D. (2001). Bioavailable Estradiol May Be an Important Determinant of Osteoporosis in Men: The MINOS Study. J. Clin. Endocrinol. Metab. 86: 192-199 [Abstract] [Full Text]  
• Amin, S., Zhang, Y., Sawin, C. T., Evans, S. R., Hannan, M. T., Kiel, D. P., Wilson, P. W.F., Felson, D. T. (2000). Association of Hypogonadism and Estradiol Levels with Bone Mineral Density in Elderly Men from the Framingham Study. ANN INTERN MED 133: 951-963 [Abstract] [Full Text]  
• Jones, M. E. E., Thorburn, A. W., Britt, K. L., Hewitt, K. N., Wreford, N. G., Proietto, J., Oz, O. K., Leury, B. J., Robertson, K. M., Yao, S., Simpson, E. R. (2000). Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc. Natl. Acad. Sci. USA 97: 12735-12740 [Abstract] [Full Text]  
• Soyka, L. A., Fairfield, W. P., Klibanski, A. (2000). Hormonal Determinants and Disorders of Peak Bone Mass in Children. J. Clin. Endocrinol. Metab. 85: 3951-3963 [Full Text]  
• Zborowski, J. V., Cauley, J. A., Talbott, E. O., Guzick, D. S., Winters, S. J. (2000). Bone Mineral Density, Androgens, and the Polycystic Ovary: The Complex and Controversial Issue of Androgenic Influence in Female Bone. J. Clin. Endocrinol. Metab. 85: 3496-3506 [Full Text]  
• Katz, M. S. (2000). Geriatrics Grand Rounds: Eve's Rib, or a Revisionist View of Osteoporosis in Men. J Gerontol A Biol Sci Med Sci 55: M560-M569 [Abstract] [Full Text]  
• Kaufman, J M, Johnell, O, Abadie, E, Adami, S, Audran, M, Avouac, B, Sedrine, W B., Calvo, G, Devogelaer, J P, Fuchs, V, Kreutz, G, Nilsson, P, Pols, H, Ringe, J, Van Haelst, L, Reginster, J Y (2000). Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 59: 765-772 [Abstract] [Full Text]  
• Rochira, V., Faustini-Fustini, M., Balestrieri, A., Carani, C. (2000). Estrogen Replacement Therapy in a Man with Congenital Aromatase Deficiency: Effects of Different Doses of Transdermal Estradiol on Bone Mineral Density and Hormonal Parameters. J. Clin. Endocrinol. Metab. 85: 1841-1845 [Abstract] [Full Text]  
• Manolagas, S. C. (2000). Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis. Endocr. Rev. 21: 115-137 [Abstract] [Full Text]  
• Marcus, R., Leary, D., Schneider, D. L., Shane, E., Favus, M., Quigley, C. A. (2000). The Contribution of Testosterone to Skeletal Development and Maintenance: Lessons from the Androgen Insensitivity Syndrome. J. Clin. Endocrinol. Metab. 85: 1032-1037 [Abstract] [Full Text]  
• Van Wyk, J. (1999). Insulin-Like Growth Factors and Skeletal Growth: Possibilities for Therapeutic Interventions. J. Clin. Endocrinol. Metab. 84: 4349-4354 [Full Text]  
• (1999). Estrogen Receptor Gene Polymorphism, But Not Estradiol Levels, Is Related to Bone Density in Healthy Adolescent Boys: A Cross-Sectional and Longitudinal Study. J. Clin. Endocrinol. Metab. 84: 4597-4601 [Abstract] [Full Text]  
• (1999). Estrogen: Consequences and Implications of Human Mutations in Synthesis and Action. J. Clin. Endocrinol. Metab. 84: 4677-4694 [Abstract] [Full Text]  
• Iqbal, F., Michaelson, J., Thaler, L., Rubin, J., Roman, J., Nanes, M. S. (1999). Declining Bone Mass in Men With Chronic Pulmonary Disease* : Contribution of Glucocorticoid Treatment, Body Mass Index, and Gonadal Function. Chest 116: 1616-1624 [Abstract] [Full Text]  
• Deladoëy, J., Flück, C., Bex, M., Yoshimura, N., Harada, N., Mullis, P. E. (1999). Aromatase Deficiency Caused by a Novel P450arom Gene Mutation: Impact of Absent Estrogen Production on Serum Gonadotropin Concentration in a Boy. J. Clin. Endocrinol. Metab. 84: 4050-4054 [Abstract] [Full Text]  
• Wilson, J. D. (1999). The Role of Androgens in Male Gender Role Behavior. Endocr. Rev. 20: 726-737 [Abstract] [Full Text]  
• Bilezikian, J. P. (1999). Osteoporosis in Men. J. Clin. Endocrinol. Metab. 84: 3431-3434 [Full Text]  
• Libanati, C., Baylink, D. J., Lois-Wenzel, E., Srinivasan, N., Mohan, S. (1999). Studies on the Potential Mediators of Skeletal Changes Occurring during Puberty in Girls. J. Clin. Endocrinol. Metab. 84: 2807-2814 [Abstract] [Full Text]  
• Raisz, L. G. (1999). Physiology and Pathophysiology of Bone Remodeling. Clin. Chem. 45: 1353-1358 [Abstract] [Full Text]  
• Robertson, K. M., O'Donnell, L., Jones, M. E. E., Meachem, S. J., Boon, W. C., Fisher, C. R., Graves, K. H., McLachlan, R. I., Simpson, E. R. (1999). Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene. Proc. Natl. Acad. Sci. USA 96: 7986-7991 [Abstract] [Full Text]  
• Khosla, S, Melton, L J III, Riggs, B L (1999). Osteoporosis: gender differences and similarities. Lupus 8: 393-396 [Abstract]  
• Maor, G., Segev, Y., Phillip, M. (1999). Testosterone Stimulates Insulin-Like Growth Factor-I and Insulin-Like Growth Factor-I-Receptor Gene Expression in the Mandibular Condyle--A Model of Endochondral Ossification. Endocrinology 140: 1901-1910 [Abstract] [Full Text]  
• Weise, M., De-Levi, S., Barnes, K. M., Gafni, R. I., Abad, V., Baron, J. (2001). Effects of estrogen on growth plate senescence and epiphyseal fusion. Proc. Natl. Acad. Sci. USA 98: 6871-6876 [Abstract] [Full Text]